Understanding cancer immunotherapy with genomics

Immunotherapies have shown incredible promise as a form of cancer treatment

Publishing interest in immunotherapy research has been growing

But the data often reveal variability in patient responses

So how can we determine which therapy will yield a favorable response in a given patient?

Today there are over 2,000 open clinical trial sites studying immunotherapy for cancer

Clinical studies of exceptional responders... have highlighted NRAS mutation status, total neoantigen load, and a neoantigen-derived tetrapeptide signature as possible correlates of response to ipilimumab in metastatic melanoma.

Discover more with NGS

www.illumina.com/immuno-oncology

24 samples, 1 run

Thousands of genes

NGS

IHC analysis

8 samples 1 gene

For Research Use Only. Not for use in diagnostic procedures.


*For Research Use Only. Not for use in diagnostic procedures.

For Research Use Only. Not for use in diagnostic procedures.

For Research Use Only. Not for use in diagnostic procedures.

For Research Use Only. Not for use in diagnostic procedures.